A share price of Prime Medicine Inc [PRME] is currently trading at $2100000.0, up 5932634%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PRME shares have gain 41.78% over the last week, with a monthly amount glided 76.17%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Prime Medicine Inc [NASDAQ: PRME] stock has seen the most recent analyst activity on May 27, 2025, when Citigroup downgraded its rating to a Neutral but kept the price target unchanged to $1.50 for it. Previously, JP Morgan downgraded its rating to Neutral on May 20, 2025. On May 20, 2025, downgrade downgraded it’s rating to Neutral. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $10 on December 10, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $10 as its price target on May 20, 2024. Citigroup upgraded its rating to Buy for this stock on May 16, 2024, but kept the price target unchanged to $10. In a note dated April 22, 2024, Chardan Capital Markets initiated an Buy rating and provided a target price of $17 on this stock.
Prime Medicine Inc experienced fluctuations in its stock price throughout the past year between $1.11 and $6.75. Currently, Wall Street analysts expect the stock to reach $17.25 within the next 12 months. Prime Medicine Inc [NASDAQ: PRME] shares were valued at $2100000.0 at the most recent close of the market. An investor can expect a potential drop of -100.0% based on the average PRME price forecast.
Analyzing the PRME fundamentals
Trailing Twelve Months sales for Prime Medicine Inc [NASDAQ:PRME] were 3.85M which represents 146.02% growth. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -4.96%, Pretax Profit Margin comes in at -4.86%, and Net Profit Margin reading is -4.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -1.25 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Prime Medicine Inc [NASDAQ:PRME] is 4.78. Also, the Quick Ratio is 4.78, while the Cash Ratio stands at 2.68. Considering the valuation of this stock, the price to sales ratio is 70.59, the price to book ratio is 2.54.
Transactions by insiders
Recent insider trading involved Liu David R., 10% Owner, that happened on Jun 16 ’25 when 21000.0 shares were purchased. 10% Owner, Liu David R. completed a deal on Jun 11 ’25 to buy 21000.0 shares. Meanwhile, Chief Business Officer Brudnick Richard bought 20000.0 shares on May 20 ’25.
